NEW YORK (GenomeWeb News) - Genizon Biosciences and pharmaceutical giant Pfizer have reached a licensing and collaboration agreement that gives Pfizer diagnostic rights to Genizon's research programs in Alzheimer's, attention deficit hyperactivity disorder, and endometriosis.
 
Pfizer has agreed to pay Genizon upfront license fees and will also fund the company’s research on genetic variations associated with those diseases. Pfizer will also buy an equity stake in the company, subject to certain closing conditions.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.